Form 4: Hepion Pharmaceuticals Director Receives Stock Grant
Insider Transaction (Form 4)
James Gordon Liddy, a Director of Hepion Pharmaceuticals, Inc., received 299,000 shares of common stock on August 19, 2026.
Summary
- Grant/award: acquired 299,000 Stock Options on August 19, 2026; holds 299,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James Gordon Liddy — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Grant/award | Stock Options | 299,000 | — | — | 299,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Grant/award (299,000 shares) |
Keywords
insider transaction, Form 4, HEPA, Hepion Pharmaceuticals, Inc., neutral, James Gordon Liddy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.